Search
Displaying 191–200 of 689 for “retinitis clinical trial”
-
A Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
Research NewsA Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
-
Quarterly vision webinars providing key information impacting our community.
-
New Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients
Research NewsThe report also concludes that vitamin E supplementation accelerates vision loss for RP patients
-
Curing Blindness, Part 2: Dick’s Story
Beacon StoriesStem-cell-based therapies – including those derived from a patient’s blood or skin – are among the many cutting-edge approaches to treatments the Foundation has funded for decades.
-
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Research NewsMerger will provide additional capital for gene therapy development.
-
The Foundation Fighting Blindness, the world’s leading private funding source for retinal degenerative disease research, will host online continuing medical education (CME and COPE) courses throughout the year. The continuing education courses will review a number of topics related to care and management of patients with inherited retinal diseases.
-
Optogenetics: Hope for Vision Restoration for Advanced Retinal Diseases
Research NewsEarly, encouraging results from two human studies — trials launched by Bionic Sight and GenSight — are putting optogenetic therapies in the spotlight for patients with advanced vision loss from retinal conditions.
-
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
Research NewsThe company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Research NewsEditas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
